These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30609269)

  • 1. Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease.
    Abraham AA; Lang H; Meier ER; Nickel RS; Dean M; Lawal N; Speller-Brown B; Wang Y; Kean L; Bollard CM
    Pediatr Blood Cancer; 2019 May; 66(5):e27601. PubMed ID: 30609269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological role of CD4
    ElAlfy MS; Adly AAM; Ebeid FSE; Eissa DS; Ismail EAR; Mohammed YH; Ahmed ME; Saad AS
    Immunol Res; 2018 Aug; 66(4):480-490. PubMed ID: 29926339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease.
    Adly AA; Ismail EA; Andrawes NG; Mahmoud MM; Eladawy R
    Cytokine; 2016 Mar; 79():52-8. PubMed ID: 26765484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cell subsets and receptor expression in peripheral blood mononuclear cells of a healthy Korean population: Reference range, influence of age and sex, and correlation between NK cell receptors and cytotoxicity.
    Phan MT; Chun S; Kim SH; Ali AK; Lee SH; Kim S; Kim SH; Cho D
    Hum Immunol; 2017 Feb; 78(2):103-112. PubMed ID: 27884732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Original Research: Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era.
    Hankins JS; Penkert RR; Lavoie P; Tang L; Sun Y; Hurwitz JL
    Exp Biol Med (Maywood); 2016 Apr; 241(7):749-54. PubMed ID: 26940953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
    Rodriguez A; Duez P; Dedeken L; Cotton F; Ferster A
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27022. PubMed ID: 29512872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic effects of hydroxyurea in sickle cell anemia.
    Lederman HM; Connolly MA; Kalpatthi R; Ware RE; Wang WC; Luchtman-Jones L; Waclawiw M; Goldsmith JC; Swift A; Casella JF;
    Pediatrics; 2014 Oct; 134(4):686-95. PubMed ID: 25180279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells.
    Ohkawa T; Seki S; Dobashi H; Koike Y; Habu Y; Ami K; Hiraide H; Sekine I
    Immunology; 2001 Jul; 103(3):281-90. PubMed ID: 11454057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
    J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications.
    Tantawy AA; Adly AA; Ismail EA; Darwish YW; Ali Zedan M
    Blood Cells Mol Dis; 2014 Dec; 53(4):189-93. PubMed ID: 25065856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophils remain detrimentally active in hydroxyurea-treated patients with sickle cell disease.
    Barbu EA; Dominical VM; Mendelsohn L; Thein SL
    PLoS One; 2019; 14(12):e0226583. PubMed ID: 31869367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers.
    Madden NA; Jones GL; Kalpatthi R; Woods G
    J Pediatr Hematol Oncol; 2014 Aug; 36(6):e382-6. PubMed ID: 24714503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy.
    Nickel RS; Osunkwo I; Garrett A; Robertson J; Archer DR; Promislow DE; Horan JT; Hendrickson JE; Kean LS
    Br J Haematol; 2015 May; 169(4):574-83. PubMed ID: 25753210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood.
    Heitzer AM; Longoria J; Okhomina V; Wang WC; Raches D; Potter B; Jacola LM; Porter J; Schreiber JE; King AA; Kang G; Hankins JS
    Br J Haematol; 2021 Oct; 195(2):256-266. PubMed ID: 34272726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunoediting of natural killer cells by human nasopharyngeal carcinoma cell line: altered expression of KIRs and NKG2D receptors leads to reduction of natural killer cell-mediated cytolysis].
    Guo KY; Mei JZ; Yao KT
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):247-9. PubMed ID: 17425963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional capacity of natural killer cells in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients.
    Queiroz GAN; Mascarenhas REM; Vieillard V; Andrade RL; Galvão-Castro B; Grassi MFR
    BMC Infect Dis; 2019 May; 19(1):433. PubMed ID: 31101076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.
    Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
    Health Qual Life Outcomes; 2017 Jul; 15(1):136. PubMed ID: 28679417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of central nervous system disease from pediatric to young adulthood in sickle cell anemia.
    Champlin G; Hwang SN; Heitzer A; Ding J; Jacola L; Estepp JH; Wang W; Ataga KI; Owens CL; Newman J; King AA; Davis R; Kang G; Hankins JS
    Exp Biol Med (Maywood); 2021 Dec; 246(23):2473-2479. PubMed ID: 34407676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.